PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PACB vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


PACBCRSP
YTD Return-82.06%-12.03%
1Y Return-85.02%11.95%
3Y Return (Ann)-59.94%-23.49%
5Y Return (Ann)-25.02%6.31%
Sharpe Ratio-0.960.25
Daily Std Dev87.90%58.97%
Max Drawdown-97.34%-81.61%
Current Drawdown-96.56%-73.78%

Fundamentals


PACBCRSP
Market Cap$393.89M$4.58B
EPS-$1.21-$1.94
PEG Ratio-0.17-0.21
Revenue (TTM)$200.52M$371.21M
Gross Profit (TTM)$53.47M-$570.70M
EBITDA (TTM)-$287.20M-$202.70M

Correlation

-0.50.00.51.00.4

The correlation between PACB and CRSP is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Performance

PACB vs. CRSP - Performance Comparison

In the year-to-date period, PACB achieves a -82.06% return, which is significantly lower than CRSP's -12.03% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%500.00%December2024FebruaryMarchAprilMay
-79.65%
290.84%
PACB
CRSP

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Pacific Biosciences of California, Inc.

CRISPR Therapeutics AG

Risk-Adjusted Performance

PACB vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PACB
Sharpe ratio
The chart of Sharpe ratio for PACB, currently valued at -0.96, compared to the broader market-2.00-1.000.001.002.003.004.00-0.96
Sortino ratio
The chart of Sortino ratio for PACB, currently valued at -1.86, compared to the broader market-4.00-2.000.002.004.006.00-1.86
Omega ratio
The chart of Omega ratio for PACB, currently valued at 0.73, compared to the broader market0.501.001.500.73
Calmar ratio
The chart of Calmar ratio for PACB, currently valued at -0.87, compared to the broader market0.002.004.006.00-0.87
Martin ratio
The chart of Martin ratio for PACB, currently valued at -1.84, compared to the broader market-10.000.0010.0020.0030.00-1.85
CRSP
Sharpe ratio
The chart of Sharpe ratio for CRSP, currently valued at 0.25, compared to the broader market-2.00-1.000.001.002.003.004.000.25
Sortino ratio
The chart of Sortino ratio for CRSP, currently valued at 0.86, compared to the broader market-4.00-2.000.002.004.006.000.86
Omega ratio
The chart of Omega ratio for CRSP, currently valued at 1.09, compared to the broader market0.501.001.501.09
Calmar ratio
The chart of Calmar ratio for CRSP, currently valued at 0.18, compared to the broader market0.002.004.006.000.18
Martin ratio
The chart of Martin ratio for CRSP, currently valued at 0.66, compared to the broader market-10.000.0010.0020.0030.000.66

PACB vs. CRSP - Sharpe Ratio Comparison

The current PACB Sharpe Ratio is -0.96, which is lower than the CRSP Sharpe Ratio of 0.25. The chart below compares the 12-month rolling Sharpe Ratio of PACB and CRSP.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00December2024FebruaryMarchAprilMay
-0.96
0.25
PACB
CRSP

Dividends

PACB vs. CRSP - Dividend Comparison

Neither PACB nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PACB vs. CRSP - Drawdown Comparison

The maximum PACB drawdown since its inception was -97.34%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for PACB and CRSP. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%December2024FebruaryMarchAprilMay
-96.56%
-73.78%
PACB
CRSP

Volatility

PACB vs. CRSP - Volatility Comparison

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 74.87% compared to CRISPR Therapeutics AG (CRSP) at 11.56%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%December2024FebruaryMarchAprilMay
74.87%
11.56%
PACB
CRSP

Financials

PACB vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items